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The aim of this study was to develop a simple, field-practical, and effective in vitro method for determining
the sensitivity of fresh erythrocytic Plasmodium vivax isolates to a range of antimalarials. The method used is
a modification of the standard World Health Organization (WHO) microtest for determination of P. falciparum
drug sensitivity. The WHO method was modified by removing leukocytes and using a growth medium supple-
mented with AB serum. We successfully carried out 34 in vitro drug assays on 39 P. vivax isolates collected
from the Mae Sod malaria clinic, Tak Province, Thailand. The mean percentage of parasites maturing to
schizonts (six or more merozoites) in control wells was 66.5% 5.9% (standard deviation). This level of growth
in the control wells enabled rapid microscopic determination (5 min per isolate per drug) of the MICs of
chloroquine, dihydroartemisinin, WR238605 (tafenoquine), and sulfadoxine. P. vivax was relatively sensitive to
chloroquine (MIC  160 ng/ml, 50% inhibitory concentration [IC50]  49.8 ng/ml) and dihydroartemisinin
(MIC 0.5 ng/ml, IC50 0.47 ng/ml). The poor response of P. vivax to both tafenoquine (MIC 14,000 ng/ml,
IC50  9,739 ng/ml) and sulfadoxine (MIC  500,000 ng/ml, IC50  249,000 ng/ml) was due to the slow action
of these drugs and the innate resistance of P. vivax to sulfadoxine. The in vitro assay developed in our study
should be useful both for assessing the antimalarial sensitivity of P. vivax populations and for screening new
antimalarials in the absence of long-term P. vivax cultures.
Each year, Plasmodium vivax is responsible for approxi-
mately 70 to 80 million cases of malaria worldwide (7). Al-
though P. vivax causes less mortality than P. falciparum, it still
causes significant worldwide mortality. Antimalarial drug re-
sistance in P. vivax was first reported in 1989, some 30 years
after chloroquine resistance was reported in P. falciparum (11).
Simple in vitro susceptibility tests for P. falciparum have
been available since 1968 (9). However, the development of
similar in vitro susceptibility tests for P. vivax has been prob-
lematic because of the poor in vitro growth of P. vivax. In the
absence of an in vitro test for determining the susceptibility of
P. vivax to antimalarials, investigators have been limited to in
vivo protocols. Although in vivo protocols are a direct measure
of the clinical efficacy of antimalarials, they are often difficult
to carry out and subject to individual variations in patient
immune status. In vitro tests provide a valuable adjunct to in
vivo drug susceptibility tests, especially when comparing tem-
poral and spatial variations in Plasmodium sp. susceptibility to
antimalarials.
Recent advances in in vitro culture techniques (i.e., specially
modified and serum-enriched media) have enabled the short-
term culture of P. vivax (3). The aim of this study was to
develop a simple, practical, and effective in vitro method for
determining the sensitivity of fresh erythrocytic P. vivax isolates
to a range of antimalarials. All of the antimalarials tested in
this study, except WR238605 (tafenoquine), specifically target
the erythrocytic stages of Plasmodium sp. WR238605 is a long-
acting 8-aminoquinoline related to primaquine and is active
against all stages of Plasmodium sp.
MATERIALS AND METHODS
Predosed drug plates. Chloroquine phosphate was purchased from Sterling-
Winthrop (Sydney, Australia). The antifolate sulfadoxine (fanasil) was obtained
from Hoffmann-La Roche (Basel, Switzerland). The Walter Reed Army Institute
of Research (Washington, D.C.) supplied WR238605 (tafenoquine) and dihy-
droartemisinin. A stock solution of each drug was prepared in methanol in glass
vials coated with a 0.2% (vol/vol) AquaSil water solution (Pierce) to prevent the
drug from binding to the glass surface. One or two dilutions of each drug were
subsequently made in methanol to obtain the drug concentration desired for
testing. Twenty microliters of the final drug solution was added to each well of a
96-well microculture plate (Nunc), and twofold serial dilutions were made in
methanol. The charged plates were dried in an incubator at 37°C overnight,
covered with Plate Sealer (Linbro), and stored at 4°C. Randomly selected,
predosed plates were checked against the K1 P. falciparum strain before and
after the study to assess drug activity.
Parasites. Plasmodium sp. isolates were collected from malaria patients re-
porting to the Mae Sod (Thailand) government malaria clinic and to Australian
Army health service facilities in East Timor and Australia. All patients were
briefed on the project and provided informed consent prior to collection of blood
by venipuncture. Blood was collected in sodium or lithium heparin collection
tubes. The chloroquine- and pyrimethamine-resistant K1 strain of P. falciparum
used in this study is maintained in continuous culture at the Australian Army
Malaria Institute (Brisbane).
Drug assay. The drug assay method used was based on the standard World
Health Organization microtest (10) for determination of P. falciparum drug
sensitivity. This methodology was modified by removing leukocytes from the
malaria-infected blood sample and using a growth medium supplemented with
AB human serum. Details of this modification are given below.
Prior to the start of the assay, a 10-ml syringe tipped with a small quantity of
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glass wool was filled with 5 ml of CF11 cellulose powder (Whatman), covered
with foil, and then autoclaved. When ready to use, the CF11 column was wetted
with 4 ml of a phosphate-buffered saline (PBS) solution (Polysciences, Inc.). Two
milliliters of whole blood parasitized with 1,000 to 50,000 ring stage P. vivax
parasites per l was gently mixed with 2 ml of PBS and added slowly to the CF11
column. The blood was then washed through the column by the addition of
approximately 5 ml of PBS. When the blood dripping into the collection tube
from the column started to turn clear, the collection tube was centrifuged at 200
 g for 5 min. The supernatant was removed, the pellet was resuspended in 5 ml
of RPMI medium (Gibco), and the mixture was centrifuged at 200 g for 5 min.
The supernatant was removed, and the pellet was resuspended to a hematocrit of
40% in AB human serum. One milliliter of this blood-serum mixture was added
to 9 ml of McCoy’s 5A medium (Gibco) containing 20% AB human serum.
Fifty microliters of this blood-medium mixture (4% hematocrit) was added to
each well of the predosed drug plates. Drug plates containing the blood-medium
mixture were incubated in a gas chamber containing 5% CO2, 5% O2, and 90%
N2 at 37.5°C, until50% of the ring stage parasites had matured to schizonts (24
to 36 h). After incubation, the plates were allowed to stand for 30 min in a
semivertical position. The supernatant was then removed, erythrocytes were
resuspended in the remaining fluid, and a thick blood film was made from each
well. Blood films were then subjected to Romanowsky staining and examined by
oil immersion microscopy (magnification, 1,000). The number of normal schi-
zonts per 200 asexual stage parasites was determined in each blood film. Results
were calculated as follows: % control  (number of schizonts/treated well)/
number of schizonts in control wells.
The MIC of drug was the minimum concentration at which more than 99% of
the parasites, relative to the control, were inhibited from developing to schizonts
(parasites with six or more chromatin dots). Degenerate schizonts (normal ap-
pearance except that the chromatin dot appears smudged and out of shape) were
not counted. The dose-response data were analyzed by nonlinear regression
analysis (Table Curve software; Jandel Scientific) to obtain the 50% inhibitory
concentrations (IC50s) (geometric means). The experiment was repeated twice
for each isolate.
RESULTS
Eight-seven percent (34 of 39) of the P. vivax isolates col-
lected at the Mae Sod malaria clinic were successfully evalu-
ated. A mean of 66.5% (standard deviation  5.9%) ring stage
parasites in the control wells developed into schizonts. This
level of development allowed rapid (5 min per isolate per drug)
microscopic determination of the MICs of chloroquine, dihy-
droartemisinin, tafenoquine, and sulfadoxine (Table 1). The
MIC of artemisinin primarily affected ring stage parasites. The
small number of parasites that progressed to the pigmented
trophozoite stage showed extensive vacuolation of the cyto-
plasm. The sensitivity of P. vivax field isolates from Mae Sod to
dihydroartemisinin can be seen in Fig. 1B (IC50  0.47 ng/ml).
MICs of chloroquine, WR238605, and sulfadoxine halted the
growth of P. vivax at the pigmented trophozoite and late amoe-
boid stages. Abnormal schizonts were present at all concentra-
tions of WR238605 and sulfadoxine except the highest. Abnor-
mal schizonts had chromatin dots that were irregular in shape
and size and contained large quantities of hemozoin pigment
in a patchy, poorly staining cytoplasm. The relatively low ac-
tivity of chloroquine (IC50  49.8 ng/ml) and the very low
activities of WR238605 (IC50  9,739 ng/ml) and sulfadoxine
(IC50  249,000 ng/ml) are presented in Fig. 1A, C, and D,
respectively. Quality control checks of the predosed drug
plates before and 1 month after the study revealed no signifi-
cant loss of antimalarial activity against the K1 strain of P.
falciparum.
DISCUSSION
This study demonstrated that it is possible to measure the
sensitivity of fresh erythrocytic isolates of P. vivax to a range of
antimalarials in a field setting. There have been no reported
cases of chloroquine-resistant P. vivax in Thailand, and all of
the P. vivax patients from the Mae Sod malaria clinic who were
enrolled in this study were satisfactorily treated with chloro-
quine. Although the patients responded well to chloroquine
treatment, our in vitro studies revealed that the MIC for P.
vivax in Mae Sod was fourfold higher than that for a chloro-
quine-sensitive strain of P. falciparum, FC27 (Table 1). How-
ever, the MICs for isolates of P. vivax from Australian Army
patients whose chloroquine treatment failed were half of those
for P. falciparum with a much higher level of resistance. These
observations may be due to chloroquine resistance mechanism
differences between P. vivax and P. falciparum (13) or may
result from specific features of the in vitro test. Unlike P.
falciparum, we have no knowledge of chloroquine uptake or
TABLE 1. Median MICs of various antimalarial compounds obtained from field isolates of P. vivax and P. falciparum from the Mae Sod
malaria clinic and from other isolates of P. vivax and P. falciparum and in vivo concentrations of the antimalarials tested
Antimalarial test agent
MIC99 (ng/ml)
Mean maximum in vivo concn (ng/ml)
P. vivax P. falciparum
Chloroquine 160,a 330c 660,b 660,d 40e 141 (whole blood) (25 mg of base/kg in
three doses over a 48-h period [1])
Dihydroartemisinin 0.5a 4.0,b 1.0d 100 (plasma) (K. Rieckmann and B.
Kotecka, unpublished data)
WR238605 14,000a 5,000,b 7,000,d 14,000f 1,200 (whole blood) (M. D. Edstein,
unpublished data)
Sulfadoxine 500,000a 500,0000,d 30,000e 150,000 (plasma) (K. Rieckmann,
unpublished data)
a Isolates from Mae Sod malaria clinic patients successfully treated with chloroquine (n  34).
b Isolates from Mae Sod malaria clinic patients (n  5).
c Isolates from Australian Army malaria patients deployed in Papua New Guinea who were not be cured by chloroquine (K. Rieckmann and B. Kotecka, unpublished
data) (n  6).
d K1 strain of P. falciparum (resistant to chloroquine and sulfadoxine).
e FC27 strain of P. falciparum (sensitive to chloroquine and sulfadoxine).
f Isolates from East Timor (Russell et al., unpublished data).












efflux in P. vivax and until such work is done, it will be difficult
to speculate on the reason for the different chloroquine MICs
for P. vivax and P. falciparum (2, 6).
Dihydroartemisinin is an active metabolite of artesunate, an
antimalarial commonly used in Thailand for the treatment of
P. falciparum infection. P. vivax was highly sensitive to dihy-
droartemisinin in comparison to the other drugs and P. falci-
parum (Table 1). Our results agree with those of Pukrittay-
amee et al. (8), who found that the artemisinin derivatives were
the most potent and rapidly acting of the antimalarials tested
in vivo against P. vivax infections. As with P. falciparum, we
observed that dihydroartemisinin inhibited P. vivax at the early
ring stage. The apparent vacuolation observed in the cytoplasm
of P. vivax parasites treated with dihydroartemisinin may be
due to the oxidative action common to all artemisinin-derived
antimalarials (12). In combination with a longer-acting drug
such as chloroquine, artesunate may prove to be an effective
antimalarial treatment that can delay the onset of chloroquine
resistance in P. vivax in Thailand.
The poor in vitro response of P. vivax to both WR238605 and
sulfadoxine may be due to the slow action of these drugs and/or
the innate resistance of P. vivax to sulfadoxine (4, 5). We have
sequenced the dhps gene from four of the Mae Sod P. vivax
isolates and found sequence polymorphisms consistent with
the resistance phenotype shown in Table 1 (Qin Chen, per-
sonal communication). Another major factor contributing to
the poor response of P. vivax to sulfadoxine is the presence of
p-aminobenzoic acid and folate in the media used (Fig. 1D).
The presence of these agents in the media shortcut the anti-
folate action of sulfadoxine. Unfortunately folate-reduced me-
dia, such as RPMI LPLF (Gibco), usually used in antifolate
drug assays, do not support P. vivax growth. This emphasizes
the need to establish new (and elevated) baseline MICs of
antifolates for P. vivax.
Unlike those of artemisinin and chloroquine, the MICs of
both WR238605 and sulfadoxine were significantly greater
than the mean maximum concentrations of these drugs after
their administration in vivo. Although there are problems with
comparing drug concentrations from in vitro blood-medium
mixtures (4% hematocrit) to in vivo concentrations (40% he-
FIG. 1. In vitro responses of P. vivax field isolates (n  34) to various concentrations of chloroquine (A), dihydroartemisinin (B), WR238605
(C), and sulfadoxine (D), measured as the mean percentage of parasites developing to mature schizonts  the standard deviation, after 28 to 36 h
of incubation. The IC50s shown on the graphs were calculated on a logistic dose-response curve (Jandel Scientific) that is not shown on the graphs.












matocrit), this information is included in Table 1 as a point of
clinical reference for our in vitro data. Longer incubation pe-
riods may reduce the MICs so that they fall within the range of
drug concentrations observed in vivo.
The absence of long-term P. vivax cultures and the difficul-
ties associated with the use of a primate model have slowed the
development of new antimalarials against P. vivax. Although
this assay technique is best suited to longitudinal studies of the
susceptibility of P. vivax to antimalarial drugs, it may also have
utility for the screening of new drugs targeting this species.
Such screening can best be done in areas where the drug
susceptibility of fresh isolates of P. vivax has been well char-
acterized.
The in vitro assay developed during this study used a wide
range of drug concentrations (i.e., 5, 10, 20, 40, 80, 160, 320,
and 660 ng of chloroquine/ml) to determine, very broadly, the
levels of antimalarial susceptibility in previously unstudied ar-
eas. For more precise determination of drug susceptibility, the
results of the initial assay should be used to target a particular
drug range with smaller concentration intervals. For example,
if parasite maturation is inhibited between 80 and 320 ng/ml,
the new plate concentrations should be 80, 120, 160, 200, 240,
280, and 320 ng/ml, thus removing possible statistical biases
inherent in the use of nonstandard intervals. The narrowing of
drug concentrations will be more sensitive in detecting the
emergence of R1 drug resistance and provide better informa-
tion for future studies correlating the in vivo and in vitro
responses of P. vivax to drugs. MICs calculated microscopically
(directly from the slide rather than extrapolated from a math-
ematical model) by using well-defined drug concentration in-
tervals are easier to calculate and may prove to be more clin-
ically relevant than IC50s.
This assay technique provides field scientists with an average
ability in microscopy a relatively simple method by which to
determine the susceptibility of P. vivax to various drugs (drug
MICs). This technique avoids the use of expensive or danger-
ous reagents (monoclonal antibodies or radioisotopes), expen-
sive equipment (beta counters or robotic plate washers and
dispensers), complex parasite age grading techniques, and
mathematical models. Furthermore, the whole procedure can
be carried out on the bench (without a laminar-flow hood) in
25 to 37 h. It is hoped that this procedure will provide a
valuable adjunct to clinical studies in areas of endemicity,
where the true drug susceptibility of P. vivax can be obscured
by various degrees of immunity acquired by patients before
their treatment with antimalarial drugs.
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